Dr. John Cush RheumNow
6 years 8 months ago
RA woman on Otezla, Kevzara, 10 pred, w/ no response, Now has SJC 9, TJC 11! Prev failed MTX, ETN, ADA, ABA, IL-6. What would treat w/?
QD Clinic - The Reluctant Rheumatologist & Pegloticase
When Should You Use Pegloticase?
Dr. John Cush RheumNow
6 years 8 months ago
Spanish study of 78 RA pts shows that Rituximab (#RTX) use was associated with a lower risk of functional respiratory decline compared with non-exposure (HR 0.51; 95% CI 0.31, 0.85). Higher w/ UIP; lower with steroids, disease activity & lower duration https://t.co/jyUXbmQDYl
Dr. John Cush RheumNow
6 years 8 months ago
Open label study of Abatacept in 79 patients with primary Sjogrens syndrome showed no difference between those treated wtih ABA vs Placebo. https://t.co/tUfAn40k9S
Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.
A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).
Dr. John Cush RheumNow
6 years 8 months ago
New Am Gastroenterology Assn Guidelines on Rx of Ulcerative colitis list infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and tofacitinib for moderate to severe UC. Rec against TOFA until failing a TNFi; against using MTX. https://t.co/b0Xap3ijK7
Dr. John Cush RheumNow
6 years 8 months ago
"If you have an important point to make, don't try to be subtle or clever. Use a pile driver. Hit the point once. Then come back and hit it again. Then hit it a third time - a tremendous whack." -Winston Churchill
NEJM NEJM
6 years 8 months ago
Placebo and nocebo effects are powerful and pervasive in clinical practice. Neurobiologic mechanisms, information offered about treatment, prior encounters with a drug or procedure, and the therapeutic milieu can all generate these effects.
Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.
QD Clinic - EULAR RA Guidelines, Part 5
When to Withdraw DMARDs & Biologics
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
QD Clinic - EULAR RA Guidelines, Part 4
Adding Biologics or JAK inhibitors
Obesity has been shown to be a risk factor for the onset of rheumatoid arthritis (RA) and also shown to affect outcomes by impairing responses to many DMARD therapies. A Swiss study of RA patients undergoing bariatric surgery failed to show that bariatric surgery and weight loss had any effect on the incidence of RA.
